deltatrials
Terminated PHASE3 INTERVENTIONAL 4-arm NCT05028569

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects With Episodic Migraine

Sponsor: AbbVie

Conditions Episodic Migraine
Interventions BOTOX Placebo
Updated 33 times since 2021 Last updated: Nov 24, 2025 Started: Nov 5, 2021 Primary completion: Nov 6, 2024 Completion: Nov 6, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated early due to lack of efficacy from the primary analysis results.

Other terminated trials from AbbVie

See all terminations from AbbVie

Listed as NCT05028569, this PHASE3 trial focuses on Episodic Migraine and remains terminated or withdrawn. Sponsored by AbbVie, it has been updated 33 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

33 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE3

    Status: Completed → Terminated

  2. Sep 2025 — Jan 2026 [monthly]

    Completed PHASE3

  3. Jan 2025 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Dec 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 28 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE3

  4. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE3

  5. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

  6. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  7. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  8. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  9. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  10. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  11. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  12. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  13. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  14. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  15. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  16. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  17. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  18. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  19. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  20. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  21. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  22. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  23. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  24. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  25. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  26. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  27. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  28. Sep 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Albuquerque, United States , Allentown, United States , Ames, United States , Amherst, United States , Ann Arbor, United States , Austin, United States , Barcelona, Spain , Bellevue, United States , Berlin, Germany and 107 more locations